Startups get one genuinely large non-dilutive route — federal R&D funding through SBIR and STTR, reauthorized through 2031. Everything else is smaller, and most of it is not a grant at all.
Open programs in the OpenGrants database whose listings mention startups. Refreshed on every site build.
For a startup, non-dilutive funding is mostly one thing: federal R&D money through SBIR and STTR. Phase I reaches $323,090 and Phase II $2,153,927 without SBA approval, the programs were reauthorized through September 30, 2031, and the government takes no equity.
Nothing else in the non-dilutive category is remotely that large. State programs are useful and usually smaller. Equity-free fellowships are real and brutally competitive. Accelerators mostly are not grants at all.
So the first question is not where to look. It is whether you qualify for the one route that matters.
SBIR pays you to resolve a technical risk — a scientific or engineering uncertainty whose answer is genuinely unknown.
That is a narrower gate than it sounds, and it is where most startups fall out. If your hard problem is distribution, or sales, or finding product-market fit, you do not have an SBIR project. Those are real and difficult problems; they are not the ones this money buys.
If you do have a technical risk, the second question is which agency, and the answer turns on how each one solicits. NSF and NIH run open calls where you propose your own idea. DoD publishes topics describing what it needs and buys against them. Bringing your own idea to a topic-driven agency is the most common expensive mistake in the program — covered in detail in the NSF and DoD guides.
Several states add matching funds or bridge grants on top of a federal SBIR award. The application is usually short, because you have already done the hard work of winning the federal award, and the money is genuinely additional.
Most founders never ask. Your state’s technology or economic development agency is the place to start, and an SBDC advisor will usually know the answer immediately.
A large share of what gets marketed to startups as “grants” is something else:
The test is simple: if ownership changes hands, it is not a grant, whatever the marketing says.
Startups needing runway this quarter. SBIR timelines run in months, and there is an unfunded gap between phases that has killed otherwise healthy companies. This is strategic capital, not emergency cash.
Companies whose ownership will not survive screening. The 2026 reauthorization made national security due diligence mandatory across the program — foreign affiliations, sources of investment capital, licensing arrangements and country-of-concern relationships are now examined. Work out your position before building a strategy on this route.
Non-technical businesses. A well-run services company, a retailer, a restaurant — these are legitimate businesses with no SBIR path. The small business guide covers what actually exists for them, which is less than the internet suggests.
SBIR funds the resolution of a scientific or engineering uncertainty. A startup whose challenge is distribution, sales or product-market fit does not have an SBIR project, however good the business.
NSF and NIH let you propose your own idea. DoD publishes topics and buys against them. This is the highest-leverage early decision and the most common expensive mistake.
SAM.gov with a UEI, SBIR company registration, then agency systems. Weeks, not days, and every one is a hard gate.
Several states add matching funds or bridge grants on top of a federal SBIR award. This is free money for paperwork you have already done, and most founders never ask.
The interval between Phase I ending and Phase II starting is unfunded and has killed otherwise healthy companies. Plan it before you need it.
Accelerators, "grants" bundled with investment, and credit programs vary enormously. If ownership changes hands, it is not a grant, whatever it is called.
